SCHEMBL489850

SCHEMBL489850

Cc1c(C(C)C)ccc(C=CC(=O)O)c1C(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.52
MAPK1 P28482 1/20 0.44
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CA4 P22748 3/20 0.39
NFKB1 P19838 1/20 0.39
MIF P14174 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.35
ESR1 P03372 2/20 0.35
PTGER1 P34995 1/20 0.35
PTGER4 P35408 1/20 0.35
PTGER3 P43115 1/20 0.35
PTGER2 P43116 1/20 0.35
LMNA P02545 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
HCAR2 Q8TDS4 3/20 0.35
HDAC3 O15379 1/20 0.35
TNKS O95271 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480692 0.87 KDM4E (0.49) KDM4EMAPK1CA1CA2CA4
SCHEMBL490186 0.80 KDM4E (0.49) KDM4EMAPK1CA1CA2CA4
SCHEMBL1072586 0.80 KDM4E (0.55) KDM4EMAPK1CA1CA2CA4
SCHEMBL1173259 0.79 KDM4E (0.66) KDM4EMAPK1CA1CA2CA4
SCHEMBL5271345 0.77 KDM4E (0.46) KDM4EMAPK1CA1CA2CA4
SCHEMBL18797918 0.74 CA1 (0.52) KDM4EMAPK1CA1CA2CA4
SCHEMBL5179255 0.73 KDM4E (0.76) KDM4EMAPK1CA1CA2CA4
SCHEMBL819054 0.73 CA1 (0.56) KDM4EMAPK1CA1CA2CA4
SCHEMBL28414685 0.73 CA1 (0.56) KDM4EMAPK1CA1CA2CA4
SCHEMBL8218747 0.72 KDM4E (0.66) KDM4EMAPK1CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100047185-A1 ACTVIE SUBSTANCE COMBINATION ISDIN S.A. (ES) 2010-02-25 US claimed
WO-2008083975-A1 LIGHT-STABILIZED COMPOSITION ISDIN S.A. (ES) 2008-07-17 WO claimed
WO-2008083974-A1 ACTIVE SUBSTANCE COMBINATION ISDIN S.A. (ES) 2008-07-17 WO claimed
WO-2008067928-A1 UV ABSORBING COMPOSITIONS CONTAINING A PYRROLYLTRIAZINE ISDIN S.A. (ES) 2008-06-12 WO claimed
US-20260078211-A1 A SOLID PARTICLE OF ORGANOSILICON-FUNCTIONAL CO-POLYMER, MANUFACTURING PROCESS THEREOF, AND COSMETICS COMPRISING SAID SOLID PARTICLE DOW TORAY CO LTD (JP) 2026-03-19 US disclosed
US-20260076892-A1 GEL COMPOSITION AND OIL-IN-WATER COMPOSITION SHISEIDO COMPANY, LTD. (JP) 2026-03-19 US disclosed
EP-4628568-A1 GEL CLEANING AGENT AND METHOD FOR PRODUCING THE SAME Shiseido Honeycake Industries Co., Ltd. (JP) 2025-10-08 EP disclosed
US-20250283012-A1 GEL CLEANING AGENT AND METHOD FOR PRODUCING THE SAME SHISEIDO HONEYCAKE INDUSTRIES CO., LTD. (JP) 2025-09-11 US disclosed
EP-4599819-A1 GEL COMPOSITION AND OIL-IN-WATER-TYPE COMPOSITION Shiseido Company, Ltd. (JP) 2025-08-13 EP disclosed
US-20250195384-A1 COSMETIC SHISEIDO COMPANY, LTD. (JP) 2025-06-19 US disclosed
EP-4516284-A1 COSMETIC Shiseido Company, Ltd. (JP) 2025-03-05 EP disclosed
US-12138329-B2 Gel cleansing agent SHISEIDO HONEYCAKE INDUSTRIES CO., LTD. (JP) 2024-11-12 US disclosed
WO-2003066015-A1 COMPOSITION FOR SKIN WHITENING CONTAINING LYSOPHOSPHATIDYLETHANOLAMINE AS AN ACTIVE INGREDIENT DOOSAN CORPORATION (KR) 2003-08-14 WO disclosed
US-20030091603-A1 Skin preparations for external use SHISEIDO COMPANY, LTD. (JP) 2003-05-15 US disclosed
EP-1165039-A2 DERMATOLOGICAL TOPICAL COMPOSITION Pentapharm A.G. (CH) 2002-01-02 EP disclosed
EP-1153602-A1 SKIN PREPARATIONS FOR EXTERNAL USE SHISEIDO COMPANY LIMITED (JP) 2001-11-14 EP disclosed
US-6150425-A COMPRISING AN OUTER PHASE OIL AND OIL IN WATER EMULSION IN THE INNER PHASE WHICH CONTAINING WATER, AN OIL BASED INGREDIENT, A SURFACTANT AND AN AMPHIPHILIC SUBSTANCE; PREPARED BY A HIGH PRESSURE OR ULTRASONIC EMULSIFICATION SHISEIDO COMPANY, LTD. (JP) 2000-11-21 US disclosed
WO-2000057840-A2 DERMATOLOGICAL TOPICAL COMPOSITION PENTAPHARM AG (CH) 2000-10-05 WO disclosed
EP-1002515-A1 SKIN COMPOSITIONS FOR EXTERNAL USE SHISEIDO COMPANY LIMITED (JP) 2000-05-24 EP disclosed
EP-0970741-A1 O/W/O TYPE MULTIPHASE EMULSION SHISEIDO COMPANY LIMITED (JP) 2000-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260076892-A1 GEL COMPOSITION AND OIL-IN-WATER COMPOSITION SGMS1, SGMS2, CETP KDM4E 3677/4885MAPK1 2111/4885CA1 2478/4885
US-20260078211-A1 A SOLID PARTICLE OF ORGANOSILICON-FUNCTIONAL CO-POLYMER, MANUFACTURING PROCESS THEREOF, AND COSMETICS COMPRISING SAID SOLID PARTICLE FOXM1, FOXK1, TAF1L KDM4E 3029/4885MAPK1 2554/4885CA1 991/4885
US-20030091603-A1 Skin preparations for external use CUTA, POLR1C, ACMSD KDM4E 592/4885MAPK1 3899/4885CA1 2923/4885
US-12138329-B2 Gel cleansing agent MPG, PARG, CHIA KDM4E 690/4885MAPK1 3427/4885CA1 2818/4885
US-20100047185-A1 ACTVIE SUBSTANCE COMBINATION UGT2B17, TACR2, UGT1A1 KDM4E 3725/4885MAPK1 4141/4885CA1 2294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.